Literature DB >> 29718017

Invasive penile squamous cell carcinoma.

Lauren M Ogrich1, Landon E Stigall2, William B Tyler3, Eric W Hossler4.   

Abstract

Invasive penile squamous cell carcinoma (PSCC) is a rare malignancy with considerable morbidity and mortality. Because a delayed or incorrect diagnosis can have a devastating outcome, physicians should maintain a high index of clinical suspicion for PSCC in patients presenting with penile lesions, particularly in young or middle-aged patients in whom presentation of PSCC is uncommon. We report the case of a 27-year-old circumcised man who presented with invasive PSCC following a diagnosis of condyloma 8 years prior. The patient underwent robotic laparoscopic bilateral pelvis and inguinal lymph node dissection and re-excision of the primary PSCC, with one of 15 superficial right inguinal lymph nodes testing positive for squamous cell carcinoma. Given the patient's single-node positivity as well as the risks associated with chemotherapy with respect to his concurrent medical conditions, close follow-up with repeat imaging was planned following surgery. This case highlights the importance of biopsy in any lesion recalcitrant to conventional treatment modalities regardless of age. Early detection and treatment of PSCC can prevent organ dysfunction, loss of organ, or even death.

Entities:  

Mesh:

Year:  2018        PMID: 29718017

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  2 in total

Review 1.  Robot-assisted endoscopic inguinal lymphadenectomy: A review of current outcomes.

Authors:  Gilberto José Rodrigues; Giuliano Betoni Guglielmetti; Marcelo Orvieto; Kulthe Ramesh Seetharam Bhat; Vipul R Patel; Rafael Ferreira Coelho
Journal:  Asian J Urol       Date:  2020-08-26

2.  Immunotherapy Combined With Chemotherapy for Postoperative Recurrent Penile Squamous Cell Carcinoma: A Case Report and Literature Review.

Authors:  Na Li; Tangpeng Xu; Zhen Zhou; Ping Li; Guohua Jia; Xiangpan Li
Journal:  Front Oncol       Date:  2022-03-23       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.